These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29764490)

  • 21. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis.
    Chen L; Chan LS; Lung HL; Yip TTC; Ngan RKC; Wong JWC; Lo KW; Ng WT; Lee AWM; Tsao GSW; Lung ML; Mak NK
    Phytomedicine; 2019 Oct; 63():153058. PubMed ID: 31394414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Pourmorteza M; Rahman ZU; Young M
    Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The natural compound gambogic acid radiosensitizes nasopharyngeal carcinoma cells under hypoxic conditions.
    Yang M; Yang Y; Cui H; Guan Z; Yang Y; Zhang H; Chen X; Zhu H; Yang X; Cai J; Cheng H; Sun X
    Tumori; 2016; 102(2):135-43. PubMed ID: 26357974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition.
    Yamazaki H; Lai YC; Tateno M; Setoguchi A; Goto-Koshino Y; Endo Y; Nakaichi M; Tsujimoto H; Miura N
    PLoS One; 2017; 12(5):e0177305. PubMed ID: 28489881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
    Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
    Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
    Drug Des Devel Ther; 2016; 10():1173-80. PubMed ID: 27042009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways.
    Zhang M; Zhou X; Zhou K
    Int J Mol Med; 2013 Mar; 31(3):621-7. PubMed ID: 23314035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BIX-01294-enhanced chemosensitivity in nasopharyngeal carcinoma depends on autophagy-induced pyroptosis.
    Li Q; Wang M; Zhang Y; Wang L; Yu W; Bao X; Zhang B; Xiang Y; Deng A
    Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1131-1139. PubMed ID: 33085742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
    Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
    Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity.
    Li J; Jiang Y; Wang P; Ke S; Yang L; Shen Y
    Anticancer Drugs; 2019 Aug; 30(7):e0747. PubMed ID: 31305293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma.
    Xia T; Tian H; Zhang K; Zhang S; Chen W; Shi S; You Y
    BMC Cancer; 2021 Sep; 21(1):1003. PubMed ID: 34493236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.